2024 Market Size And Company Share Data For Glioblastoma
"The
Latest Research Report OpportunityAnalyzer: Glioblastoma -
Opportunity Analysis and Forecasts to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Glioblastoma Market
Glioblastoma multiforme (GBM) is
characterized as a disease with some of the highest unmet needs in
oncology, with patients having a median overall survival (OS) of
between one and two years. The lack of therapies is primarily due to
the inability of drugs to penetrate the blood-brain barrier (BBB).
The GBM market is currently dominated by temozolomide and Avastin
which are considered as standards of care in newly diagnosed and
recurrent settings, respectively. Between 2014 and 2024, the market
is set to undergo substantial growth due to a number companies
developing therapies in the late-stage pipeline, which is dominated
by immunotherapies. On one hand, the main drivers of growth will be
the launch of EGFR-targeting therapies such as Rintega and ABT-414,
as well as the checkpoint inhibitor Opdivo. Furthermore, the launch
of autologous cell vaccines such as ICT-107 and DCVax-L will also
impact the GBM market. On the other hand, the GBM market constrainers
remain modest with the increasing cost-consciousness of healthcare
providers, and the launch of biosimilar bevacizumab in the 7MM (US,
France, Germany, Italy, Spain, UK and Japan).
Highlights
Key Questions Answered
- The GBM market is marked by the
presence of a number of unmet needs. What are the main unmet needs in
this market? Will the drugs under development fulfil the unmet needs
of GBM market?
- The late-stage GBM pipeline has
therapies targeting different GBM populations. Which late-stage drugs
will have the biggest impact in each patient population? Which of
these drugs will have the highest peak sales at the highest CAGR, and
why?
- Current therapies used to treat
GBM include temozolomide, Gliadel and Avastin. How will the advent of
new therapies change the drug treatment landscape for GBM? How will
the drug treatment rate change over the next five years? What are the
key drivers and barriers to this change?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/699487
Key Findings
- The main driver of the enormous
expansion of the GBM market will be the launch of Opdivo for newly
diagnosed and recurrent GBM. GlobalData forecasts significant patient
uptake for Opdivo which will supersede Avastin to become the SoC in
the recurrent setting.
- The second largest driver will
be the launch of Rintega for EGFRvIII positive GBM. Rintega uptake
would be partially facilitated by the availability of EGFRvIII
companion diagnostics, which help to identify patients most likely to
respond to the treatment.
- The approval of Rintega and
Opdivo will partially fulfil key unmet needs in the GBM space:
however, many of these unmet needs will still remain even after these
agents are launched.
- Another driver of the GBM market
is the increasing incidence of GBM cases within the 7MM. The biggest
constrainer of the GBM market is the launch of biosimilar bevacizumab
in the 7MM.
Scope
- Overview of GBM, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized GBM therapeutics
market revenue, average cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the GBM
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global GBM therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the global GBM
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global GBM therapeutics
market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
GBM therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 8
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
2.3 Upcoming Related Reports 19
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/699487
3 Disease Overview 20
3.1 Etiology and Pathophysiology
20
3.1.1 Etiology 20
3.1.2 Pathophysiology 20
3.2 Symptoms 23
4 Epidemiology 24
4.1 Disease Background 24
4.2 Risk Factors and Comorbidities
25
4.3 Global Trends 26
4.3.1 7MM Incidence Trends 26
4.3.2 7MM Trends in Relative
Survival 28
4.4 Forecast Methodology 29
4.4.1 Sources Used 29
4.4.2 Sources Not Used 33
4.4.3 Forecast Assumptions and
Methods 34
4.5 Epidemiological Forecast for
Brain Cancer (2014-2024) 36
4.5.1 Diagnosed Incident Cases of
Brain Cancer 36
4.5.2 Age-Specific Diagnosed
Incidence of Brain Cancer 38
4.5.3 Sex-Specific Diagnosed
Incident Cases of Brain Cancer 40
4.5.4 Age-Standardized Diagnosed
Incidence of Brain Cancer 42
4.5.5 Five-Year Diagnosed
Prevalent Cases of Brain Cancer 44
4.5.6 Diagnosed Incident Cases of
Brain Cancer by Type 45
4.6 Discussion 46
4.6.1 Epidemiological Forecast
Insight 46
4.6.2 Limitations of the Analysis
47
4.6.3 Strengths of the Analysis 48
5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles- Major Brands
50
5.2.1 Avastin (bevacizumab) 50
5.2.2 Temozolomide 57
5.2.3 Gliadel (carmustine wafer)
59
5.2.4 Optune (NovoTTF-100A) 61
6 Unmet Needs Assessment and
Opportunity Analysis 64
6.1 Overview 64
6.2 Identification of New
Treatment Options for Patients with rGBM Refractory to Avastin 65
6.2.1 Unmet Need 65
6.2.2 Gap Analysis 66
6.2.3 Opportunity 66
6.3 More Efficacious Treatment for
Patients with MGMT-Unmethylated Promoters 67
6.3.1 Unmet Need 67
6.3.2 Gap Analysis 67
6.3.3 Opportunity 68
6.4 Criteria to Evaluate Tumor
Response 68
6.4.1 Unmet Need 68
6.4.2 Gap Analysis 69
6.4.3 Opportunity 69
6.5 Reduce Use of Steroids in GBM
Patients 70
6.5.1 Unmet Need 70
6.5.2 Gap Analysis 70
6.5.3 Opportunity 71
6.6 Identification of Biomarkers
Predictive of Therapeutic Efficacy 71
6.6.1 Unmet Need 71
6.6.2 Gap Analysis 71
6.6.3 Opportunity 72
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment